{'fraction_non_alphanumeric': 0.031609195402298854, 'fraction_numerical': 0.0028735632183908046, 'mean_word_length': 6.260416666666667, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Real‐world effectiveness and safety of tildrakizumab in long‐term treatment of plaque psoriasis: Results from the non‐interventional, prospective, multicentre study TILOT

Plaque psoriasis is a chronic inflammatory disorder affecting the skin and impacting quality of life. Tildrakizumab (TIL) is an IL‐23 inhibitor licensed for moderate‐to‐severe plaque psoriasis. Regulatory approval of medicinal products is based on safety and efficacy data from randomized controlled trials (RCTs) which impose stringent selection criteria. Long‐term non‐interventional studies (NIS) are needed to establish effectiveness and safety in daily practice bridging the gap between RCTs and the real‐world setting.